186408-95-7

Basic information

• Product Name: 4-(2-aminoethoxy)-3-(benzenesulfonyl)-1,2,5-oxadiazole-2-oxide
• Synonyms: 4-(2-aminoethoxy)-3-(benzenesulfonyl)-1,2,5-oxadiazole-2-oxide
• CAS NO: 186408-95-7
• Molecular Weight: 285.28
• Mol File: 186408-95-7.mol
• Article Data: 29

Chemical Properties

• CAS DataBase Reference: 4-(2-aminoethoxy)-3-(benzenesulfonyl)-1,2,5-oxadiazole-2-oxide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-aminoethoxy)-3-(benzenesulfonyl)-1,2,5-oxadiazole-2-oxide(186408-95-7)
• EPA Substance Registry System: 4-(2-aminoethoxy)-3-(benzenesulfonyl)-1,2,5-oxadiazole-2-oxide(186408-95-7)

Safety Data

• Hazardous Substances Data: 186408-95-7(Hazardous Substances Data)

Upstream product

• 141-43-5 ethanolamine 
• 66074-00-8 3,4-bis(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 
• 107-15-3 ethylenediamine 
• 26690-80-2 2-(N-tert-butoxycarbonylamino)ethanol 

Downstream Products

• 1043914-08-4 3-({4-[(2-{[5-oxido-4-(phenylsulfonyl)-1,2,5-oxadiazol-3-yl]oxy}ethyl)amino]-4-oxobutanoyl}oxy)olean-12-en-28-oic acid 
• 1394345-32-4 C₁₈H₁₃N₃O₇S 
• 1394345-33-5 C₂₄H₁₈N₄O₉S₂ 

Relevant articles and documents

Tuning NO release of organelle-targeted furoxan derivatives and their cytotoxicity against lung cancer cells

We herein report a study on a set of hybrid compounds in which 3-R-substituted furoxan moieties (R = CH3, CONH2, CN, SO2C6H5), endowed with varying NO-releasing capacities, are joined to a mitochondri

Chromone 3-position nitric oxide donor derivative as well as preparation method and application thereof

The invention relates to the fields of natural medicines and medicinal chemistry, and relates to a preparation method of a series of chromone 3-position nitric oxide donor derivatives with antitumor activity and a new application of the chromone 3-position nitric oxide donor derivatives in preparation of antitumor medicines. The chromone 3-position nitric oxide donor derivative and the pharmaceutically acceptable salt thereof are shown as a general formula I in the specification. Wherein R and R1 are described in the claims and the specification.

Discovery of β-carboline-(phenylsulfonyl)furoxan hybrids as potential anti-breast cancer agents

The cytotoxicity properties of the β-carboline alkaloids have been broadly investigated. However, the potential application of β-carbolines was hindered due to the moderate activity in cancer. In the present study, thirty β-carboline-(phenylsulfonyl)furoxan hybrids (11a–j, 12a–j and 13a–j) were designed and synthesized through esterification and amidation reaction strategy, and their inhibitory activities against the human breast cancer cell lines MCF-7 and MDA-MB-231 were evaluated by CCK-8 assay. Biological evaluation presented that the most promising amide derivative 13h, substituted with p-methoxyphenyl group at position 1, generated high concentration of NO and evidently depressed the MCF-7 (IC50 = 0.89 μM) and MDA-MB-231 (IC50 = 0.62 μM) cells proliferation. Particularly, the wound healing and transwell assays demonstrated that 13h significantly inhibited the migration and invasion of MDA-MB-231cells. Furthermore, the preliminary mechanisms studies indicated that 13h induced G2/M phase arrest and apoptosis possibly causing by ROS accumulation and ROS-mediated DNA damage. Based on these considerations, 13h may be a promising antimetastatic agent for breast cancer, which is noteworthy for further exploration.